期刊
CANCER TREATMENT REVIEWS
卷 50, 期 -, 页码 68-81出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2016.08.008
关键词
Endocrine treatment; Resistance; Molecular mechanisms; New agents
类别
资金
- AstraZeneca
- MSD
- Novartis
- Pfizer
- Roche-Genentech
- Roche
- Periphagen
- Huya
- Debiofarm
- PharmaMar
- Radius
Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (similar to 70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments. Over the last two decades, improved understanding of the molecular mechanisms of endocrine resistance has been achieved, with numerous targeted agents undergoing clinical development. Despite the multifactorial genesis of endocrine resistance, fuelled not only by alternative oncogenic signaling pathways of tumor cells, but also by tumor microenvironment-mediated mechanisms, successful clinical development of new agents has been recently noted. However, predictive biomarkers for accurate 'navigation' across the different treatment options are urgently needed. In this article, we present a thorough overview of the different clinical scenarios of BC endocrine resistance, and the recent advances in endocrine treatment, we describe the basic molecular mediators of endocrine resistance and the respective targeted agents undergoing clinical development; finally, we provide our perspective on the future of BC endocrine treatment. (C) 2016 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据